Immunome, Inc. Announces Submission for Publication of Pre-Clinical Research Detailing the Importance of Antibody Cocktail for Sars-Cov-2 Treatment and Prophylaxis
October 20, 2021 at 08:00 am EDT
Share
Immunome, Inc. announced that it submitted to bioRxiv a preprint of a manuscript regarding preclinical research of the company?s SARS-CoV-2 antibody cocktail, IMM-BCP-01. The manuscript is concurrently undergoing scientific peer review for potential publication. IMM-BCP-01 contains three monoclonal, antibodies that bind to non-overlapping regions of the spike protein, including highly conserved epitopes. In preclinical testing, the antibodies exhibit combinatorial effects against multiple SARS-CoV-2 strains, including CDC variants of concern, and significantly reduces viral load in the lungs of hamsters infected with a SARS-CoV-2 reference strain. Immunome?s preclinical research demonstrates: The three antibodies, derived from human immune response, bind to the spike protein in a non-competitive manner. The first antibody binds to a sub-dominant epitope of the spike protein, which appears to be broadly conserved across all current and former SARS-CoV-2 variants of concern as well as other Betacoronaviruses and SARS-COV-1. The second antibody is also directed at a broadly conserved epitope and exhibits an avidity-based binding mechanism. The third antibody binds to a composite epitope involving the receptor binding ridge and an area adjacent to the receptor binding loop. As a cocktail, the three antibodies demonstrate enhanced anti-viral activity. Efficacious in pseudovirus neutralization against the CDC variant of concern, Delta. Shows equal or better activity against live virus in the reference and the variants tested to-date (Alpha, Beta and Gamma). Potent activation of phagocytosis and complement fixation ? known to be critical for in vivo treatment efficacy. In both treatment and prophylactic settings, at corresponding doses of up to 9 mg/kg, the cocktail potently reduced live viral titers by approximately 3.2 - 4 logs (or up to 10,000-fold) in the lungs of Syrian hamsters infected with SARS-CoV-2 virus. Published data for Sotrovimab (GSK and VIR Biotechnology), at 30 mg/kg, the highest dose tested in the prophylactic setting, show approximately a 2 log (or 100-fold) reduction in live viral titer in the lungs of Syrian hamsters infected with SARS-COV-2. This study was funded by the U.S. Department of Defense (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense?s (JPEO-CBRND) Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), in collaboration with the Defense Health Agency (DHA).
Immunome, Inc. is a biotechnology company engaged in developing targeted cancer therapies. The Company's portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, radioligand therapies and Antibody-Drug Conjugates (ADCs). Its memory B cell hybridoma technology allows for the screening and functional characterization of novel antibodies and targets. Its programs include Oncology (IMM-ONC-01), LU FAP, and SARS-CoV-2 (IMM-BCP-01). The oncology program is an antibody (IMM-ONC-01) against interleukin-38 (IL-38) a novel immune modulator for the treatment of various solid tumors. Its Targeted Effector platform uses small molecule ligands to selectively deliver drug payloads to diseased cells. It also operates AL102 and related drug candidate AL101. AL102 is an investigational small molecule gamma secretase inhibitor being evaluated in the Phase III for the treatment of desmoid tumors. AL102 is a potential once-daily oral treatment for desmoid tumors.
Immunome, Inc. Announces Submission for Publication of Pre-Clinical Research Detailing the Importance of Antibody Cocktail for Sars-Cov-2 Treatment and Prophylaxis